Novavax, Inc. (NVAX)
NASDAQ: NVAX · Real-Time Price · USD
8.70
+0.02 (0.23%)
At close: Dec 20, 2024, 4:00 PM
8.74
+0.04 (0.46%)
After-hours: Dec 20, 2024, 7:32 PM EST
Novavax Revenue
Novavax had revenue of $84.51M in the quarter ending September 30, 2024, a decrease of -54.80%. This brings the company's revenue in the last twelve months to $885.19M, down -15.68% year-over-year. In the year 2023, Novavax had annual revenue of $983.71M, down -50.36%.
Revenue (ttm)
$885.19M
Revenue Growth
-15.68%
P/S Ratio
1.41
Revenue / Employee
$573,683
Employees
1,543
Market Cap
1.39B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 983.71M | -998.17M | -50.36% |
| Dec 31, 2022 | 1.98B | 835.58M | 72.89% |
| Dec 31, 2021 | 1.15B | 670.69M | 141.02% |
| Dec 31, 2020 | 475.60M | 456.94M | 2,448.48% |
| Dec 31, 2019 | 18.66M | -15.63M | -45.57% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Indivior | 1.18B |
| Guardian Pharmacy Services | 1.17B |
| U.S. Physical Therapy | 639.06M |
| Phreesia | 405.14M |
| Immunocore Holdings | 296.31M |
| Maravai LifeSciences Holdings | 276.92M |
| Arcus Biosciences | 263.00M |
| Schrödinger | 193.35M |
NVAX News
- 8 days ago - Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million Milestone - PRNewsWire
- 11 days ago - Novavax Initiates Phase 3 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza - PRNewsWire
- 17 days ago - Novavax to sell Czech manufacturing unit to Novo Nordisk for $200 mln - Reuters
- 17 days ago - Novavax Announces Sale of Czech Republic Manufacturing Site to Novo Nordisk for $200 Million - PRNewsWire
- 4 weeks ago - Novavax, Inc. (NVAX) Jefferies London Healthcare Conference (Transcript) - Seeking Alpha
- 5 weeks ago - Moderna, Lily, Novavax, and Pfizer stocks fall after Trump nominates RFK Jr. as health secretary - Fast Company
- 5 weeks ago - Vaccine Maker Stocks Slump After RFK Jr. Nominated as HHS Head - Investopedia
- 5 weeks ago - Vaccine maker stocks fall after conspiracy theory-spreading RFK Jr. tapped to lead health department - New York Post